Valganciclovir Hydrochloride

盐酸缬更昔洛韦

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameValganciclovir Hydrochloride
Drug Alias NameValganciclovirum盐酸颉更昔洛韦缬更昔洛韦盐酸盐ValixaDarilin +[16] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitors
TargetsDNA-directed DNA polymerase
Therapy Area/IndicationsDepressive Disorder, MajorImmune Reconstitution Inflammatory SyndromeUveitis, Anterior +[14] 
Global Approved IndicationsCytomegalovirus InfectionsCytomegalovirus Retinitis
Approved Indications in ChinaCytomegalovirus InfectionsCytomegalovirus Retinitis
Original Approved Country/TerritoryUnited States
Original Approved Date2001/03/29
Country/TerritoryBelgiumCanadaUnited States +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoRoche Pharma (Schweiz) AgCheplapharm Arzneimittel Gmbh +[7] 
Inactive CompaniesRoche Pharma AgUniversity Of MinnesotaStanford University +[10] 
Active IndicationsDepressive Disorder, MajorUveitis, AnteriorUveitis +[7] 
Inactive IndicationsImmune Reconstitution Inflammatory SyndromeViremiaFatigue Syndrome, Chronic +[7] 

Other Information

ATC CodeJ05AB14
Related LinksWikipediaDrugBankKEGG